Novartis Institutes for BioMedical Research, Novartis Campus, Basel, Switzerland.
Immunol Cell Biol. 2018 Jan;96(1):81-99. doi: 10.1111/imcb.1018. Epub 2017 Dec 21.
Mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) is essential for immune responses triggered by antigen receptors but the contribution of its paracaspase activity is not fully understood. Here, we studied how MALT1 proteolytic function regulates T-cell activation and fate after engagement of the T-cell receptor pathway. We show that MLT-827, a potent and selective MALT1 paracaspase inhibitor, does not prevent the initial phase of T-cell activation, in contrast to the pan-protein kinase C inhibitor AEB071. However, MLT-827 strongly impacted cell expansion after activation. We demonstrate this is the consequence of profound inhibition of IL-2 production as well as reduced expression of the IL-2 receptor alpha subunit (CD25), resulting from defective canonical NF-κB activation and accelerated mRNA turnover mechanisms. Accordingly, MLT-827 revealed a unique transcriptional fingerprint of MALT1 protease activity, providing evidence for broad control of T-cell signaling pathways. Altogether, this first report with a potent and selective inhibitor elucidates how MALT1 paracaspase activity integrates several T-cell activation pathways and indirectly controls gamma-chain receptor dependent survival, to impact on T-cell expansion.
黏膜相关淋巴组织淋巴瘤易位蛋白 1(MALT1)对于抗原受体触发的免疫反应至关重要,但它的连接酶活性的贡献尚不完全清楚。在这里,我们研究了 MALT1 蛋白水解功能如何调节 T 细胞受体途径激活后的 T 细胞激活和命运。我们发现,一种有效的、选择性的 MALT1 连接酶抑制剂 MLT-827,并不会像全蛋白激酶 C 抑制剂 AEB071 那样,阻止 T 细胞激活的初始阶段。然而,MLT-827 在激活后强烈影响细胞的扩增。我们证明,这是由于 IL-2 产生的深度抑制以及 IL-2 受体 alpha 亚基(CD25)表达降低的结果,这是由于缺陷的经典 NF-κB 激活和加速的 mRNA 周转机制所致。因此,MLT-827 揭示了 MALT1 蛋白酶活性的独特转录特征,为广泛控制 T 细胞信号通路提供了证据。总之,这项具有有效和选择性抑制剂的首次报告阐明了 MALT1 连接酶活性如何整合几种 T 细胞激活途径,并间接控制依赖γ-链受体的存活,从而影响 T 细胞的扩增。